Myriad Genetics Statistics
Total Valuation
Myriad Genetics has a market cap or net worth of $457.10 million. The enterprise value is $518.25 million.
Important Dates
The next confirmed earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Myriad Genetics has 94.44 million shares outstanding. The number of shares has increased by 2.21% in one year.
| Current Share Class | 94.44M |
| Shares Outstanding | 94.44M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 3.30% |
| Owned by Institutions (%) | 80.24% |
| Float | 79.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 102.78 |
| PS Ratio | 0.56 |
| Forward PS | 0.52 |
| PB Ratio | 1.23 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 254.47 |
| PEG Ratio | 2.66 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.49, with a Debt / Equity ratio of 0.57.
| Current Ratio | 2.49 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 65.56 |
| Debt / FCF | n/a |
| Interest Coverage | -6.46 |
Financial Efficiency
Return on equity (ROE) is -68.45% and return on invested capital (ROIC) is -15.62%.
| Return on Equity (ROE) | -68.45% |
| Return on Assets (ROA) | -4.89% |
| Return on Invested Capital (ROIC) | -15.62% |
| Return on Capital Employed (ROCE) | -11.84% |
| Weighted Average Cost of Capital (WACC) | 11.20% |
| Revenue Per Employee | $305,370 |
| Profits Per Employee | -$135,519 |
| Employee Count | 2,700 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 8.53 |
Taxes
| Income Tax | -29.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.77% in the last 52 weeks. The beta is 1.87, so Myriad Genetics's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | -34.77% |
| 50-Day Moving Average | 4.75 |
| 200-Day Moving Average | 6.05 |
| Relative Strength Index (RSI) | 50.57 |
| Average Volume (20 Days) | 979,066 |
Short Selling Information
The latest short interest is 8.24 million, so 8.72% of the outstanding shares have been sold short.
| Short Interest | 8.24M |
| Short Previous Month | 8.76M |
| Short % of Shares Out | 8.72% |
| Short % of Float | 10.35% |
| Short Ratio (days to cover) | 3.90 |
Income Statement
In the last 12 months, Myriad Genetics had revenue of $824.50 million and -$365.90 million in losses. Loss per share was -$3.95.
| Revenue | 824.50M |
| Gross Profit | 576.60M |
| Operating Income | -67.80M |
| Pretax Income | -395.10M |
| Net Income | -365.90M |
| EBITDA | -14.10M |
| EBIT | -67.80M |
| Loss Per Share | -$3.95 |
Full Income StatementBalance Sheet
The company has $149.60 million in cash and $209.80 million in debt, with a net cash position of -$60.20 million or -$0.64 per share.
| Cash & Cash Equivalents | 149.60M |
| Total Debt | 209.80M |
| Net Cash | -60.20M |
| Net Cash Per Share | -$0.64 |
| Equity (Book Value) | 368.00M |
| Book Value Per Share | 3.94 |
| Working Capital | 198.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.80 million and capital expenditures -$15.60 million, giving a free cash flow of -$13.80 million.
| Operating Cash Flow | 1.80M |
| Capital Expenditures | -15.60M |
| Depreciation & Amortization | 53.70M |
| Net Borrowing | 84.50M |
| Free Cash Flow | -13.80M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
Gross margin is 69.93%, with operating and profit margins of -8.22% and -44.38%.
| Gross Margin | 69.93% |
| Operating Margin | -8.22% |
| Pretax Margin | -47.92% |
| Profit Margin | -44.38% |
| EBITDA Margin | -1.71% |
| EBIT Margin | -8.22% |
| FCF Margin | n/a |
Dividends & Yields
Myriad Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | -79.88% |
| FCF Yield | -3.01% |
Analyst Forecast
The average price target for Myriad Genetics is $7.64, which is 57.85% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.64 |
| Price Target Difference | 57.85% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 5.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Myriad Genetics has an Altman Z-Score of 0.22 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.22 |
| Piotroski F-Score | 5 |
